Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 21 Nov 2017 |
| Data from Phase III ALCYONE Study of Daratumumab Accepted for Oral Presentation at Annual Meeting of the American Society of Hematology | 21 Nov 2017 |
| Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma | 21 Nov 2017 |
| Genmab Achieves USD 50 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen | 17 Nov 2017 |
| Articles of Association for Genmab A/S | 15 Nov 2017 |